Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting

Mittendorf T, Smith-Palmer J, Timlin L, Happich M, Goodall G

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.1111/j.1463-1326.2009.01099.x

Indexing Status
Subject indexing assigned by CRD

MeSH
Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Germany; Humans; Hypoglycemic Agents; Insulin; Peptides; Quality-Adjusted Life Years; Venoms

AccessionNumber
22009103936

Date bibliographic record published
24/03/2010